We have engaged in offering Liraglutide (NN2211) CAS 204656-20-2 for many years. Liraglutide is a once-daily injectable derivative of the human incretin (metabolic hormone) glucagon-like peptide-1 (GLP-1). Liraglutide 204656-20-2 like a panacea that widely used to treat type 2 diabetes and obesity.

On the one hand, Liraglutide improves control of blood glucose. It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion. On the other hands, Liraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients. Our Liraglutide CAS NO. 204656-20-2 is high quality and steady. We can provide various of pakaging to meet customers requirement.

Thera. Category: Treatment of type 2 diabetes or obesity

Cas No.: 204656-20-2

Synonym: Liraglutide;Glycine, L-histidyl-L-alanyl-L-alpha-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-alpha-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-N6-(N-(1-oxohexadecyl)-L-gamma-glutamyl)-L-lysyl-L-alpha-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl-;Liraglutida;Liraglutida [inn-spanish];Liraglutide [usan:inn];Liraglutidum;Liraglutidum [inn-latin];N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)glp-1-(7-37)-peptide

Molecular Formula: C172H265N43O51

Molecular Weight: 3751.20

Assay: ≥99.%

Packing: Export worthy packing

lMaterial Safety Data Sheet: Available on request

Usage: Liraglutide is a once-daily injectable derivative of the human incretin (metabolic hormone) glucagon-like peptide-1 (GLP-1), for the treatment of type 2 diabetes or obesity.
3. Type 2 diabetes